Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast CancerEva Thomas, Miguel Martín, Josep Tabernero et al.|Journal of Clinical Oncology|2007Cited by 290
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J. Creighton, Rachel Schiff, Xiaoyong Fu et al.|Breast Cancer Research|2010Cited by 258
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni, Gianni Bonadonna, Mikhail Byakhov et al.|Journal of Clinical Oncology|2009Cited by 216
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.Rámón Colomer, Belén Lloveras, Sagrario Montero et al.|PubMed|2000Cited by 172
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative TherapyLuca Gianni, José Baselga, W. Eiermann et al.|Clinical Cancer Research|2005Cited by 165